Biocardia, INC 8-K filings

BioCardia announced positive primary endpoint results from its CardiAMP Cell Therapy trial for chronic myocardial ischemia, showing improved exercise tolerance and reduced angina.

BioCardia and CART-Tech have formed an exclusive partnership to develop and commercialize Heart3D Fusion Imaging for cardiac interventions.

BioCardia, Inc. reported increased net losses and cash burn in Q2 2025, while advancing multiple cardiovascular cell therapy clinical trials and securing a new patent.

BioCardia, Inc. announced anticipated regulatory submission timelines for its CardiAMP Cell Therapy System and Helix Transendocardial Delivery Catheter to the FDA and Japan PMDA.

BioCardia, Inc. has submitted its CardiAMP autologous cell therapy for clinical consultation with Japan's Pharmaceuticals and Medical Devices Agency, marking a significant step towards potential regulatory approval in a key market.

BioCardia, Inc. announced that Henry Ford Health has commenced patient enrollment for its pivotal Phase 3 CardiAMP HF II trial targeting ischemic heart failure.

BioCardia, Inc. has successfully completed a private placement, securing approximately $570,000 through the sale of common stock and warrants, with significant investment from its board members and executive officers.

BioCardia, Inc. announced the grant of a new United States patent for its Helix Biotherapeutic Delivery System, enhancing its intellectual property in minimally invasive cardiovascular therapy.

BioCardia announces positive two-year results from its CardiAMP HF Trial and reports its first quarter 2025 financial results, highlighting progress in its cardiovascular and pulmonary disease therapies.

BioCardia announces the start of patient enrollment at the University of Wisconsin for its Phase 3 CardiAMP HF II trial, evaluating cell therapy for ischemic heart failure.

BioCardia has announced the enrollment of the first patient in its Phase 3 CardiAMP HF II clinical trial for heart failure treatment.

BioCardia, Inc. has entered into a Securities Purchase and Registration Rights Agreement for a private placement of common stock and warrants, expected to close on April 23, 2025.

BioCardia announces that the independent Data Safety Monitoring Board (DSMB) recommended the CardiALLO Heart Failure Phase 1/2 clinical trial continue as designed after reviewing 30-day safety data from the 20 million cell dosing cohort.

BioCardia announces that Emory University School of Medicine is now enrolling patients in its Phase III CardiAMP HF II trial for ischemic heart failure.

BioCardia, Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

BioCardia, Inc. clarifies the timing of its conference call to discuss the two-year results of the CardiAMP-HF study, scheduled for today, March 31, 2025, at 4:30 PM EDT.

BioCardia announces positive two-year results from its Phase 3 CardiAMP-HF trial, demonstrating increased survival, decreased cardiac events, and improved quality of life in ischemic heart failure patients treated with CardiAMP cell therapy.

BioCardia announces its 2024 financial results, highlighting reduced operating losses and R&D expenses, and anticipates presenting CardiAMP HF Trial data at the American College of Cardiology Scientific Sessions.

BioCardia, Inc. announces the grant of a Japanese patent for its Helix biotherapeutic delivery system, expanding its patent portfolio for minimally invasive catheter-based therapies.

BioCardia completes data verification and freezes primary outcomes data for its Phase 3 CardiAMP HF study, with results slated for presentation at the American College of Cardiology 2025 Scientific Sessions.

BioCardia announces the completion of enrollment and dosing in the low dose cohort of its CardiALLO Phase I/II trial, evaluating allogeneic mesenchymal stem cells for treating ischemic heart failure.

BioCardia's Phase 3 CardiAMP HF study results will be presented at the American College of Cardiology 2025 Scientific Sessions in a late-breaking symposium.

BioCardia has announced the commercial availability of its Morph DNA steerable introducer product family, which is currently used in the company's ongoing clinical trials.

BioCardia has successfully completed a consultation with Japan's PMDA regarding the registration of its BCDA-01 therapy for ischemic heart failure, with the next consultation planned after the submission of final clinical trial data.

BioCardia reported its third quarter 2024 financial results and provided updates on its clinical trials, including the completion of patient follow-up in the CardiAMP Heart Failure Trial.

BioCardia has completed the final follow-up visit in its Phase III clinical trial for CardiAMP cell therapy for heart failure, moving closer to potential regulatory approvals.

BioCardia has regained full compliance with Nasdaq listing requirements after demonstrating adherence to the Equity Rule, following a period of balance sheet improvements and capital raising.

BioCardia successfully closed a $7.2 million public offering, priced at-the-market, to fund working capital and advance its biotherapeutic programs.

BioCardia, Inc. has entered into agreements to sell common stock and warrants in a public offering, expecting net proceeds of $6.3 million.

BioCardia has announced the pricing of an upsized public offering expected to generate $7.2 million in gross proceeds.